CL2022000927A1 - Anticuerpos dirigidos a flt3 y uso de los mismos - Google Patents
Anticuerpos dirigidos a flt3 y uso de los mismosInfo
- Publication number
- CL2022000927A1 CL2022000927A1 CL2022000927A CL2022000927A CL2022000927A1 CL 2022000927 A1 CL2022000927 A1 CL 2022000927A1 CL 2022000927 A CL2022000927 A CL 2022000927A CL 2022000927 A CL2022000927 A CL 2022000927A CL 2022000927 A1 CL2022000927 A1 CL 2022000927A1
- Authority
- CL
- Chile
- Prior art keywords
- flt3
- proteins
- antibodies directed
- pharmaceutical compositions
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915120P | 2019-10-15 | 2019-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000927A1 true CL2022000927A1 (es) | 2022-10-28 |
Family
ID=75538063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000927A CL2022000927A1 (es) | 2019-10-15 | 2022-04-12 | Anticuerpos dirigidos a flt3 y uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240228628A9 (enExample) |
| EP (1) | EP4045537A4 (enExample) |
| JP (1) | JP2022551757A (enExample) |
| KR (1) | KR20220082882A (enExample) |
| CN (1) | CN115348972A (enExample) |
| AR (1) | AR120222A1 (enExample) |
| AU (1) | AU2020366000A1 (enExample) |
| BR (1) | BR112022006817A2 (enExample) |
| CA (1) | CA3153801A1 (enExample) |
| CL (1) | CL2022000927A1 (enExample) |
| CO (1) | CO2022004743A2 (enExample) |
| IL (1) | IL292259A (enExample) |
| MX (1) | MX2022004291A (enExample) |
| PE (1) | PE20221256A1 (enExample) |
| TW (1) | TWI867066B (enExample) |
| WO (1) | WO2021076554A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| JP2024532167A (ja) * | 2021-08-16 | 2024-09-05 | ヒーモジェニックス ファーマシューティカルズ エルエルシー | 抗ｆｌｔ３抗体、ｃａｒ、ｃａｒ ｔ細胞、及び使用方法 |
| WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CA2978631C (en) * | 2015-03-09 | 2023-06-27 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to flt3 proteins |
| WO2017011803A1 (en) * | 2015-07-16 | 2017-01-19 | Cellerant Therapeutics, Inc. | Cysteine-substituted immunoglobulins |
| JP7234142B2 (ja) * | 2017-06-02 | 2023-03-07 | ファイザー・インク | Ｆｌｔ３に特異的な抗体およびその使用 |
| PE20241587A1 (es) * | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| WO2019023097A1 (en) * | 2017-07-26 | 2019-01-31 | Smet Pharmaceutical Inc | ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE |
| MX2020007291A (es) * | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
-
2020
- 2020-10-14 CN CN202080072320.1A patent/CN115348972A/zh active Pending
- 2020-10-14 PE PE2022000635A patent/PE20221256A1/es unknown
- 2020-10-14 JP JP2022522653A patent/JP2022551757A/ja not_active Ceased
- 2020-10-14 US US17/769,257 patent/US20240228628A9/en not_active Abandoned
- 2020-10-14 CA CA3153801A patent/CA3153801A1/en active Pending
- 2020-10-14 BR BR112022006817A patent/BR112022006817A2/pt not_active Application Discontinuation
- 2020-10-14 WO PCT/US2020/055480 patent/WO2021076554A1/en not_active Ceased
- 2020-10-14 MX MX2022004291A patent/MX2022004291A/es unknown
- 2020-10-14 AU AU2020366000A patent/AU2020366000A1/en active Pending
- 2020-10-14 KR KR1020227016159A patent/KR20220082882A/ko not_active Ceased
- 2020-10-14 TW TW109135527A patent/TWI867066B/zh active
- 2020-10-14 AR ARP200102839A patent/AR120222A1/es unknown
- 2020-10-14 EP EP20876423.3A patent/EP4045537A4/en active Pending
-
2022
- 2022-04-12 CL CL2022000927A patent/CL2022000927A1/es unknown
- 2022-04-13 IL IL292259A patent/IL292259A/en unknown
- 2022-04-13 CO CONC2022/0004743A patent/CO2022004743A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022004743A2 (es) | 2022-07-08 |
| KR20220082882A (ko) | 2022-06-17 |
| EP4045537A4 (en) | 2024-07-17 |
| IL292259A (en) | 2022-06-01 |
| EP4045537A1 (en) | 2022-08-24 |
| US20240228628A9 (en) | 2024-07-11 |
| WO2021076554A1 (en) | 2021-04-22 |
| TWI867066B (zh) | 2024-12-21 |
| US20240132598A1 (en) | 2024-04-25 |
| PE20221256A1 (es) | 2022-08-16 |
| CA3153801A1 (en) | 2021-04-22 |
| MX2022004291A (es) | 2022-05-10 |
| BR112022006817A2 (pt) | 2022-07-05 |
| AU2020366000A1 (en) | 2022-05-12 |
| CN115348972A (zh) | 2022-11-15 |
| JP2022551757A (ja) | 2022-12-13 |
| AR120222A1 (es) | 2022-02-02 |
| TW202124449A (zh) | 2021-07-01 |
| WO2021076554A8 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004743A2 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| CL2023002105A1 (es) | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos | |
| CO2020010345A2 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos | |
| MX2019011679A (es) | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. | |
| CY1124462T1 (el) | Συνδυαστικα παρασκευασματα για την αγωγη του καρκινου | |
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| MX2024003913A (es) | Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos. | |
| MX2022003718A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| CO2021001410A2 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
| CL2018002456A1 (es) | Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso | |
| MX2020013169A (es) | Conjugados de camptotecina. | |
| MX2022013882A (es) | Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos. | |
| CO2018001624A2 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| CL2021003343A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3. | |
| MX2019003780A (es) | Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres. | |
| ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
| MX2017005243A (es) | Reducción de la viscosidad de formulaciones farmacéuticas. | |
| AR114102A1 (es) | Anticuerpo biespecífico heterodimérico estructural natural anti-pd-1 / anti-her2 y método para su preparación | |
| BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
| MX2021014803A (es) | Anticuerpo anti-factor de crecimiento de tejido conectivo y aplicacion del mismo. | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
| CO2022011230A2 (es) | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |